Melanoma Coverage from Every Angle

Alexander N. Shoushtari, MD, on Dosing Nivolumab

Posted: Tuesday, May 8, 2018

When addressing mild to moderate adverse events of nivolumab, do you use a short course of corticosteroid during a dose interruption, or is holding the dose usually sufficient?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.